[Articles] Safety and immunogenicity of a Nipah virus vaccine (HeV-sG-V) in adults: a single-centre, randomised, observer-blind, placebo-controlled, phase 1 study

All three doses and regimens of HeV-sG-V had a tolerable risk profile and were able to induce an immune response. The induction of antibodies within 1 month of vaccination, along with the persistence afforded by two dosages, suggests the vaccine candidate has potential for reactive outbreak control and preventive use.